Abstract PURPOSE: Our preliminary report of imatinib mesylate (IM) in gastrointestinal stromal tumor (GIST) patients detailed a high response rate; however, the long-term result is still unknown. We conducted an analysis of Taiwan advanced inoperable/metastatic GIST patients treated on IM regarding survival, pattern of failure, potential prognostic factors, and mutational status. PATIENTS AND METHODS: From 2001 to 2010, patients with pathologically proven advanced inoperable/metastatic GIST receiving IM were enrolled onto this study. Data on KIT mutational status, measurable tumor size, and other potential prognostic factors were prospectively collected. Patients were followed up for a median of 33.6 months. RESULTS: There were 171 patients (106 men and 65 women) with response rate, and their clinical benefit for IM was 57.3% and 87.1%, respectively. Median progression-free survival (PFS) and overall survival (OS) for these 171 patients are 37.6 and 71.0 months, respectively. Of 171 patients, 120 (70.2%) remained on long-term IM use. Poor performance status, tumor larger than 11.5 cm, primary resistance, and the presence of an exon 9 mutation were independently associated with unfavorable PFS. Regarding OS, poor performance status, primary resistance, and tumor larger than 11.5 cm were three independently unfavorable predictors. CONCLUSIONS: The median PFS and OS of 171 GIST patients are 37.6 and 71.0 months, respectively. Poor performance status, tumor size larger than 11.5 cm, primary resistance, and an exon 9 mutation were independently associated with unfavorable PFS. Regarding OS, poor performance status, primary resistance, and tumor size larger than 11.5 cm were three independent unfavorable predictors.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. In Taiwan, the annual incidence of GIST is 13.74 per million Taiwanese [1] . Before 2001, no effective systemic treatments existed for GISTs [2] . However, the association between constitutively activated KIT and platelet-derived growth factor receptor A (PDGFRA) signaling and GIST oncogenesis provided justification for testing a small-molecule tyrosine kinase inhibitor in this tumor type [3] . Imatinib mesylate (IM) selectively inhibits certain protein tyrosine kinases: intracellular ABL kinase, chimeric BCR-ABL fusion oncoprotein of chronic myeloid leukemia, transmembrane receptor kit, and PDGFRs [4] [5] [6] [7] . GISTs express the cell surface transmembrane receptor kit with a tyrosine kinase activity. There are frequent gain-of-function mutations of kit in GISTs [3] . These mutations result in constitutive activation of kit signaling, which leads to uncontrolled cell proliferation and resistance to apoptosis [3] . IM has shown a promising clinical result for an advanced GIST patient [8] , and several trials have shown a promising effect of this target therapy [6, [9] [10] [11] . As shown in our previous preliminary study, Glivec had a significant impact on survival in patients with advanced GISTs, but the follow-up time is just 16 months and the patient number is limited [12] .
This study represented a large single-institute experience on IM use for a decade, including 171 patients with advanced GIST and followed up to a median of 33.6 months. This study examined the long-term impact of IM on patient response, survival, and the correlation of the response rate with the kit gene mutation status. We also tried to elucidate the predictors for favorable PFS and OS of Taiwanese patients with advanced and metastatic GIST receiving IM.
Materials and Methods

Patients, Study Design, and Efficacy Evaluation
From August 2001 to April 2010, 171 adult patients with histologically confirmed, advanced inoperable/metastatic GIST that expressed the CD117 antigen (as a marker of the KIT receptor) and with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) [13] were eligible. Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance score of 3 or less and adequate hematologic, renal, and hepatic function. A prospective, nonrandomized, single-center study was conducted to evaluate the effect of IM in inducing an objective response or stable disease in Taiwanese with advanced inoperable/metastatic GIST. Patients were administered 400 mg of IM in 100-mg capsules, taken orally daily with food. Patients had regular physical examinations and evaluations of performance status, body weight, complete blood count, and serum chemistry. Standard computed tomography was performed on each patient every 3 months for the first 3 years and every 6 months for the following 2 years to assess the patient's response. Tumor size was measured in at least five target lesions with the sum of the largest dimension that was used as a response evaluation indicator as described in RECIST [13] . Time to response (TTR = time point of best response − time point of IM administration) was defined as the interval for best drug response during imatinib treatment. Time to progression (TTP = time point of disease progression − time point of IM administration) was defined as the interval for worse drug response with disease progression during imatinib treatment. Progression-free survival (PFS) is defined as no progression after administration of IM. Overall survival (OS) is defined as survival after administration of IM and death as the end point of the study or December 2010. Primary resistance is defined as PFS less than 6 months. Patients underwent regular physical examinations and evaluations of performance status, body weight, complete blood cell count, and serum chemistry. The study was approved by the local institutional review board of Chang Gung Memorial Hospital, and written informed consent for drug administration and analysis of tumor-associated genetic alteration was obtained independently from each patient.
Analysis of KIT and PDGFRA Mutations
Sections were prepared from formalin-fixed, paraffin-embedded pretreatment specimens trimmed to enrich tumor cells. Polymerase chain reaction amplification of genomic DNA for KIT and PDGFRA was sent to another hospital and performed by Professor C.Y. Tzen. Amplification was analyzed for mutations as previously described [14] .
Statistical Analysis
Data were presented as percentages of patients or means with standard deviation. Numerical data were compared by an independent twosample t test. Factors found significant at P < .05 were included in a multivariate Cox proportional hazard model. Thereafter, an enter-selection procedure was applied to select the most relevant prognostic factors. Only factors that remained significant at the .05 level during the selection procedure were included in the final model. All statistical analyses were performed using SPSS computer software package (Version 10.0; SPSS, Inc, Chicago, IL). P < .05 was considered statistically significant. Table 1 summarizes the demographic features of 171 patients with advanced inoperable/metastatic GIST treated with IM. There were 
Results
Clinical Features
Treatment and Outcomes
Since 2001, in Taiwan, IM has been administered to patients with advanced inoperable/metastatic GISTs. 400 mg IM per day was given to all the 171 patients first. All of the 171 patients were followed up after administration of IM at regular intervals until death or until December 2010. Table 2 summarizes antitumor response of IM on 171 Taiwanese with advanced inoperable/metastatic GIST. Overall, 4 patients (2.3%) had CR, 94 (55.0%) had PR, 51 had SD (29.8%), and 22 had PD (12.9%). Of all GIST patients, 87.1% had a clinical benefit. Among the 171 patients, the median TTR for 4 patients who had CR was 13.0 months and that for 94 patients who had PR was 3.2 months. The median PFS for the 94 PR and 51 SD patients was 47.6 and 42.7 months, respectively. The median OS of the 94 PR and 51 SD patients was 71.0 and 80.6 months, respectively. Whereas for the 22 PD patients, the median time to progression was 2.6 months and the median OS was 17.3 months (Table 2 ). Among the 22 GIST patients with primary resistance, exon 9 is the most common cause (8 patients with exon 9 mutation), followed by exon 11 mutation (6 patients with exon 11). Of 21 GIST patients with exon 9 mutation, 8 (31%) developed primary resistance after IM treatment, whereas of 90 GIST patients with exon 11 mutation, 6 (6.7%) developed primary resistance. Hence, patients with advanced inoperable/metastatic GIST who harbored exon 9 mutation had a significantly higher chance of primary resistance when compared with those who had exon 11 mutation (8/21 exon 9 vs 6/90 exon 11, P = .001).
Spectrum of Mutations in 171 Patients with Advanced
Inoperable/Metastatic GIST Table 3 summarizes the correlation between antitumor response and mutation status of 171 Taiwanese with advanced GIST treated with IM. Tumor specimens suitable for genetic analysis were available from 122 (71.3%) of the 171 patients with advanced GIST. Overall, 111 (90.9%) of the 122 examined GISTs had activated mutations of kit exons 9 and 11. Nine (7.4%) had no mutation of KIT, and only two patients with PDGFRA mutation (exon 18 V840). Of 122 GISTs, 21 (17.2%) expressed exon 9 mutation and 90 (73.8%) had exon 11 mutation. In 90 patients with GISTs harboring kit exon 11 mutations, the CR and PR rates (overall response rate = 74.4% [4 CR and 63 PR]) are significantly higher than those of 9 of 21 patients with tumors containing a kit exon 9 mutation (overall response rate = 40.9% [9 PR]) (P = .0005; Table 3 ). Regarding clinical benefit, GIST patients harboring kit 11 mutations also had a significantly higher clinical benefit than those harboring kit 9 mutations (P = .0005).
Survival Analysis for 171 Patients with Advanced Inoperable/Metastatic GIST Receiving Imatinib
The median follow-up period after IM was 33.6 months (range = 1.6-110.9 months). Of these 171 patients, 87 developed progression (50.9%) and 51 (29.8%) died because of GIST. The 171 Taiwanese with advanced inoperable/metastatic GIST had a median PFS of 37.64 months and OS of 71.0 months (Figures 1 and 2) . Tables 4  and 5 summarize the survival analysis of PFS and OS of these 171 GIST patients after IM treatment, including clinical features, tumor size, mutational status, and laboratory data. Univariate survival analysis revealed that age older than 65 years, poor performance with ECOG 2 or 3, exon 9 mutation, tumor size larger than 11.5 cm, and primary resistance are associated with inferior PFS of GIST patients receiving IM treatment (Figure 3) . Multivariate Cox proportional hazard analysis demonstrated that poor performance status, exon 9 mutation, tumor size larger than 11.5 cm, and primary resistance are associated with an inferior PFS of GIST patients receiving IM treatment. Regarding OS, univariate survival analysis revealed that age older than 65 years, poor performance with ECOG 2 or 3, poor nutritional status, and tumor size larger than 11.5 cm are associated with inferior OS of GIST patients receiving IM treatment (Figure 4) . However, multivariate Cox proportional hazard analysis demonstrated that good performance status, tumor size less than 11.5 cm, and good response were the only three independent prognostic factors that favorably affected OS of patients with advanced inoperable/metastatic GIST after IM treatment (Table 5) .
Discussion This is one of the largest series in a single center that dealt with patients with advanced inoperable/metastatic GIST treated with IM for a decade.
Several issues of interest emerged with the longer follow-up of Taiwanese patients with advanced inoperable/metastatic GIST on this study. First, IM, a semiselective inhibitor of uncontrolled kinase activity of KIT and PDGFRA, can control advanced GIST in a large proportion of patients for more than 5 years. The 171 Taiwanese patients with advanced inoperable/metastatic GIST had a median PFS of 37.64 months and OS of 71.0 months after a median follow-up of up to 33.6 months. Of 171 patients, 87 (50.9%) developed progression and 51 (29.8%) died because of GIST. These results are substantially superior to the B2222 study [11] but similar to reports on Poland [15] and Korea [16] (median PFS was 40.5 and 48.0 months, respectively). Because a substantial fraction of patients (87/171, 50.9%) on this study eventually faced disease progression, this finding may imply that salvage therapy (potentially including increased imatinib doses [17] , alternative tyrosine kinase inhibitors [18] , or surgery [19] ) is effective. Multimodality therapy is paramount for progression of GIST after IM treatment and to delay of death from GIST. Second, similar to the B2222 study, long-term PFS and OS on IM were equivalent between patients with GIST achieving an objective response and even complete response by RECIST and those whose disease merely stabilized [11] . This study showed that the most definitive unfavorable factor for PFS and OS of patients with advanced inoperable/metastatic GIST is primary resistance. The reason for primary resistance as the most definitive unfavorable factor for PFS is obvious because primary resistance is defined as PFS of less than 6 months. However, it is still of note that the estimated median OS of patients with primary resistance was quite short (17.3 months), which suggests that salvage therapy for this population is less effective and/or that the mechanisms of resistance to tyrosine kinase inhibition between this population and those with secondary imatinib resistance are quite different.
Third, tumor size assessments based on RECIST demonstrated that tumor size is the other important predictor for PFS as well as OS in this study. Although response assessment systems using density and/or smaller changes in size are much more precise [20] , it is likely that they would yield information on potential responses more quickly. Different from the B2222 study, tumor bulk was represented by quantifying five measurable largest lesions as depicted by RECIST [13] . Similar to the B2222 study, patients with the bulkiest tumors had significantly inferior PFS and OS compared to those who had smaller tumors. This supported the hypothesis that a larger number of tumor cells should be quantitatively proportional to a greater likelihood of harboring more resistant clones.
Fourth, similar to the B2222 study, our study showed that performance status and mutational status are independently associated with PFS [11] . Exon 9 mutation had the poorest PFS after IM treatment. Only performance status is also independently associated with OS in this study. Contrary to the B2222 study, this study did not show that sex, neutrophil count, albumin level, as well as other laboratory data were independently associated with either PFS or OS.
Finally, GISTs particularly present a variety of genomic mutations across two different receptor tyrosine kinase genes. KIT or PDGFRA mutation in Taiwanese patients with clinically advanced inoperable/ metastatic GIST was examined in this study. In response rate for IM, similar to our previous report, IM induced a sustained objective response in more than half of the Taiwanese patients with advanced GISTs Translational Oncology Vol. 4, No. 6, 2011 IM and GIST Expressing KIT: Taiwan Experience Yeh et al. (96/171, 57.3%). Gain-of-function mutations of PDGFRA were only recently discovered in GISTs [21] , and studies have reported that PDGFRA and kit mutations are mutually exclusive [14] . However, the incidence of PDGFR mutation in Taiwanese patients with advanced inoperable/metastatic GIST is very low (1.6%) compared with series from the west. Racial difference may be the reason for the difference in genetic alteration between the west and Taiwanese patients. A subset of GIST tumors in this study lacked detectable kit or PDGFRA mutations. Although such GISTs lack apparent genomic mutations, they can express phosphorylated kit or PDGFRA proteins that likely contribute to tumor proliferation or survival [14] . Contrary to the observation of Heinrich et al. [22] , GISTs lacking a detectable kinase mutation had a similar clinical benefit for imatinib to tumor with an exon 11 mutation or an exon 9 mutation (77.8% vs 93.9% and 77.8% vs 61.9%, P = .154 and P = .675, respectively). Regarding the relationship between response rate and kinase mutation, kit exon 11 and exon 9 mutations predict a favorable response to IM. In this study, activated mutations of kit exons 11 and 9 are found in most patients (90.9%) with GIST. Similar to the study of Heinrich et al. [22] , the clinical benefit did differ between the groups of patients whose GISTs had KIT exons 9 and 11 mutation (61.9% vs 93.3%, P = .0005). This observation confirmed metaGIST that the KIT oncoproteins encoded by exon 9 should be escalated to a higher dose of IM, although the number of cases is still limited.
In conclusion, the median PFS and OS of or 171 GIST patients are 37.6 and 71.0 months. Poor performance status, tumor size larger than 11.5 cm, primary resistance, and an exon 9 mutation were independently associated with an unfavorable PFS. Regarding OS, poor performance status, primary resistance, and tumor size larger than 11.5 cm were three independent unfavorable predictors.
